Institutional investors are, by and large, unable to own shares in companies with market valuations of less than $100 million, which means most sellside analysts don't write research on very
To cast a spotlight on disruptive biotechnology stocks, Raghuram "Ram" Selvaraju of Aegis Capital Corp. taps his experience as a molecular biologist, preclinical investigator and
Billions of dollars have been spent chasing molecular targets in neurological diseases that now appear to be worthless. Effective therapies remain rare. But the market is enormous—and low
Acorda Therapeutics Inc is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.
| Website: | www.acorda.com |
| Email: | tsaccavino@acorda.com |
| Main Phone: | +1 914 347-4300 |
| Address: | 420 Saw Mill River Road |
| State: | NY |
| City / Town: | Ardsley |
| Country: | US |
| Postal Code: | 10502 |
| Exchange: | NGS |
| CEO: | Ron Cohen |
| Employees: | 168 |
| NAICS: | Biological Product (except Diagnostic) Manufacturing(325414) |
Institutional investors are, by and large, unable to own shares in companies with market valuations of less than $100 million, which means most sellside analysts don't write research on very
To cast a spotlight on disruptive biotechnology stocks, Raghuram "Ram" Selvaraju of Aegis Capital Corp. taps his experience as a molecular biologist, preclinical investigator and
Billions of dollars have been spent chasing molecular targets in neurological diseases that now appear to be worthless. Effective therapies remain rare. But the market is enormous—and low
Technical analysis can be a fickle beast. No matter how good you get at reading charts and spotting patterns, your careful research can go right out the window in a moment if something major
For the entire furor surrounding the upcoming implementation of “Obamacare” at the start of next year, few have been able to advance anything that resembles a comprehensive assessment
The Dow Jones Industrial Average declined to a day’s low at 12,583.41 then cut the day’s loss by more than a half. The NASDAQ declined to 2852.88 then rebounded to a day’s high at 2898.05,
The Dow Jones Industrial Average traded up from 11,965.23 up to 12,051.28 versus its 200-day simple moving average at 11,975 then declined to 11,880.69 before recovering above the 200-day into the
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 26 | 65 |
| Number of Buys | 7 | 26 |
| Number of Sells | 19 | 39 |
| Net Activity | -223764 | 617477 |
| Last 10 Buys | Shares |
|---|---|
| Matthew Sirovich | 1,000 |
| Matthew Sirovich | 1,000 |
| Matthew Sirovich | 1,000 |
| Ron Cohen | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| David M. Lawrence | 1,000 |
| David M. Lawrence | 1,000 |
| Matthew Sirovich | 1,000 |
| Lauren M. Sabella | 1,000 |
| Matthew Sirovich | 1,000 |
| David M. Lawrence | 1,000 |
| David M. Lawrence | 1,000 |
| David M. Lawrence | 1,000 |
| David M. Lawrence | 1,000 |
| David M. Lawrence | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 31 | 31 | 31 | 31 |
| Low Target Price Estimate | 17 | 17 | 17 | 17 |
| Mean Target Price Estimate | 23.29 | 23.29 | 23.29 | 23.29 |
| Standard Deviation | 5.5 | 5.5 | 5.5 | 5.5 |
| Date of Most Recent Estimate | 05/30/18 | 05/30/18 | 05/22/18 | 05/30/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-13 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-12 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-12 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| 8-K | Report of unscheduled material events or corporate changes. | 5 | 2018-05-29 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-23 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-22 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-22 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-17 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 5 | 5 | 4 | 5 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 |
| Mean Rec. | 2.75 | 2.75 | 2.5 | 2.56 |
© 2021 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
